INTRODUCTION
Paediatric chronic fatigue syndrome (CFS) or myalgic encephalitis (ME) affectseffects 0.57-2.4% 1-4 of children and is disabling with important impacts on mood 5 6 school attendance 4 7 8 quality of life 9 and family functioning 10 . It is defined as generalised fatigue causing disruption of daily life, persisting after routine tests and investigations have failed to identify an obvious underlying cause 11 . A minimum of three months of fatigue is required before the diagnosis can be made 12 . On average, those affected miss a year of school overall and half are bedbound at some stage 13 14 .
There is a limited evidence base for treatment of paediatric CFS/ME 12 15 16 . Three randomized trials have shown that Cognitive Behavioural Therapy (CBT) delivered individually 1717 , with biofeedback 1818 or via the internet 19 is effective at six months compared to waiting list or usual medical care. All three studies reported improvements in fatigue, school attendance and a reduction in disability.
Family-focused CBT appears to be as effective as psycho-education in terms of school attendance at six months and recovery at 24 months 20 21 . However, even with effective treatment, over a third of children 19 20 have not recovered at six months and 12 months 2222 and 21% 21 to 36% 22 are still unwell (for example attending school less than 70% of the time) at 24 months. There is therefore an urgent need to find more effective treatments.
The Lightning Process (LP) is developed from osteopathy, life coaching and neuro-linguistic programming and is used for a variety of conditions including CFS/ME. Clients read information, attend three group sessions and then receive follow-up phone calls 23 . 23 . More than 250 children use LP for their CFS/ME each year in the UK (at a cost of ~£620 each), but there are no reported studies investigating its effectiveness, cost-effectiveness or side effects. LP is not available in the NHS.
Having shown that recruitment, randomisation and data collection was feasible and acceptable 2424 we conducted a randomized trial to investigate the effectiveness and cost-effectiveness of LP in addition to Specialist Medical Care (SMC), compared to SMC alone, for children with CFS/ME.
METHODS

Study design and participants
A detailed description of the study protocol has been reported 25 . Between September 2010 and April 2013 we recruited participants after clinical assessment by the Bath/Bristol paediatric CFS/ME service, a large regional and national NHS specialist service. 25 . Between September 2010 and September 2013 we recruited participants after clinical assessment by the Bath/Bristol paediatric CFS/ME service, a large regional and national NHS specialist service. We tested the feasibility of running this trial with a feasibility phase (29 th September 2010 to 18 th September 2012). We determined the trial was feasible in June 2012 and registered the full trial (31 st July 2012). We applied for an amendment to recruit children into the full trial as opposed to a feasibility trial (see web table 1 for detailed description of amendments). Full trial first randomisation was the 19 th September 2012. We continued seamlessly with participant recruitment without any interim between-group comparison of participant outcome data from the feasibility phase.. Children from both phases (feasibility and full) were analysed. Children were diagnosed with CFS/ME after a thorough assessment which included screening for other disorders associated with fatigue 12 .
Baseline data were collected at this assessment. Children were eligible if they had CFS/ME, were aged 12-18, spoke English and were not housebound.
Randomisation and masking
Allocation to trial arms was in equal proportions using minimisation by age (12-15/16-18 years) and gender, weighted towards minimising the imbalance in trial arms with probability 0.8. Allocation was concealed using a telephone-based interactive voice response system, created and maintained by the Bristol Randomised Trials Collaboration, and accessed by the recruiting researcher. This was an open study: the randomized intervention was conveyed after obtaining consent, during the Effectiveness & Cost effectiveness 6 & 12 months ADC Resubmission recruitment interview so that participants, parents, therapists and researchers were aware of treatment allocation. Data analyses were conducted using masked treatment codes.
Interventions
All participants were offered Specialist Medical Care (SMC) 12 which focused on improving sleep and using activity management to establish a baseline level of activity (school, exercise and social activity) which is then gradually increased. Sessions were delivered by a range of trained and supervised professionals including doctors, psychologists, physiotherapists and occupational therapists in family-based rehabilitation consultations. Follow-up sessions were either face to face or by telephone. The number and timing of the sessions were agreed with the family depending on each adolescent's needs and goals. Those with significant anxiety or low mood were offered additional CBT. Participants could choose to use physiotherapist-delivered Graded Exercise Therapy, which provides detailed advice about exercise and focuses on an exercise programme rather than other activities.
Participants randomized to SMC+LP were asked to read information about LP and complete an assessment form with their parents to identify their goals and describe what they had learnt. They then had a telephone call with an LP practitioner (Appendix 1) to discuss attending an LP course consisting of three four-hour sessions on consecutive days run with groups of two to five young people. Each had a theory session with taught elements on the stress response, how the mind and body interact, and how thought processes can be either helpful or negative. This was followed by group discussion where the language used was discussed and in some cases challenged, and where participants were encouraged to think about what they could take responsibility for and change. In the practical session, participants identified a goal they wished to achieve (such as standing for longer) and were given different cognitive (thinking) strategies before and whilst the goal was attempted. They were also asked to identify a goal to attempt at home. After the course, young people were offered at least two follow-up phone calls with a LP Practitioner. 
Outcomes
The primary outcome was the SF-36 physical function subscale (SF-36-PFS 26 ) analysed as a continuous variable collected at six months post-randomisation. We chose the SF-36 based on qualitative work conducted in the feasibility phase of the study. 24 We have reported that parents and participants "commented that the school attendance primary outcome did not accurately reflect what they were able to do, particularly if they were recruited during, or had transitioned to, A levels during the study". In addition, "we were aware of some participants who had chosen not to increase school attendance despite increased activity." We therefore concluded that: "trials involving 17 and 18 year olds should consider alternative primary outcome measures to school attendance as it is difficult to assess for those transitioning from GCSEs to A levels, and may not be appropriate for those who do not consider school attendance their primary goal". At this stage, our recommendation was that a "full study uses other primary outcomes, such as the SF-36 or the Chalder Fatigue Scale and uses school attendance as a secondary outcome." These findings informed our application for our ethical amendment to a full study in 2011 (see Web table 1). And were published in our feasibility paper in 2013. 24 Qualitative interviews with SMILE participants then formed part of a larger study which described the conceptual model for paediatric CFS/ME. 27 In this study, physical activity (or disability) is described by children as being pivotal because of the impacts on social participation and emotional wellbeing. Whilst school was deemed to be an important contextual factor, these qualitative results led us to choose the SF-36-PFS as a primary outcome with school attendance as a secondary outcome. There was no analysis of any outcome data during or after the feasibility phase until the entire trial was completed.
Secondary outcomes were the SF-36-PFS at three and 12 months, and school attendance (days per week), the Chalder Fatigue scale 2728 , pain (visual analogue scale), Hospital Anxiety and Depression Scale (HADS) 29 , Spence Children's Anxiety Scale (SCAS) 30 and quality-adjusted life years (QALYs, derived from the EQ-5D-Y) 28 at three, six and 12 months. Pain was measured by a visual analogue scale at six months. All were self-completed by participants. Participants also completed the Hospital Anxiety and Depression Scale (HADS) 29 and the Spence Children's Anxiety Scale (SCAS) 30 at assessment, 31 at three, six and 12 months. At three, six and 12 months parents completed an adapted 4 item Work Productivity and Activity Impairment: General Health V2.0 (WPAI:GH) questionnaire (V2.0) 3132 and a resource use questionnaire assessing their child's health service use (e.g. GP or specialist care), educational service use (e.g. school counsellor), health related travel and other family costs.
Time windows for questionnaire return were pre-specified as six weeks after the three month follow-up, six weeks before or up to three months after the six month follow-up, and three months before or after the 12 month follow-up. Those who had not responded within one week were sent a reminder letter with a reduced set of questionnaires (SF-36-PFS, Chalder Fatigue scale and school attendance). From February 2011 non-responders were telephoned by a researcher and the SF-36-PFS and Chalder Fatigue scale were completed over the phone to improve follow up rates.
Sample size
We used aA consensus definition for a small clinically important difference of 10 points on the SF-36-PFS at six months follow up is 10 points 3233 . 32. However, we did not want to 50 participants in each arm are required tomiss a smaller but still potentially important effect of as low as 8 points. To detect a between-group difference of 8 to 10 points on the SF-36-PFS (SD 10) at six months with 90% power and, 1% two-sided significance. and standard deviation of 10 requires between 32 and 50 participants per group for analysis. Allowing for 10 to 20% non-collection of primary outcome data, we aimed to recruit between 80 to(32*2/0.8) and 112 (50*2/0.9) participants.
Statistical analysis
The statistical analysis plan was agreed by the study management group and published on our website prior to analyses. The primary analysis compared mean SF-36-PFS scores at six months according to randomized allocation among participants with measured outcomes, using multivariable linear regression adjusting for baseline values of the outcome, baseline age and gender. Similar regression analyses were conducted for secondary outcomes. Sensitivity analyses of the primary outcome adjusted for variables for which there was baseline imbalance; excluded those recruited up to 31 January 2011 preceding the protocol amendment to allow collection of follow up data by phone; and used multiple imputation of missing data (see Web Appendix 1 for details)..
Missing items in partially completed scales (Chalder Fatigue and SF-36-PFS) or subscales (SCAS and
HADS anxiety and depression) were imputed using the mean of completed items, if only one item (or two for the SCAS subscales) was missing. If more items were missing the whole scale or subscale was scored as missing. Twelve month outcome data were analysed similarly. We conducted a repeated measures analysis using all follow-up SF-36-PFS scores, with and without an interaction between allocation arm and time, to investigate whether between-group differences remained constant over time. We did not analyse three month outcomes except in this repeated measures analysis for SF-36-PFS as these were unlikely to be informative since the primary follow up was at six months. We estimated the Complier Average Causal Effect (CACE), using instrumental-variables linear regression estimated via the generalized method of moments (GMM), of LP among compliers, defined as participants in the SMC+LP arm who completed all of the LP course.
Pre-specified subgroup analyses explored differences in treatment effect according to baseline age (<15 versus 15 to 17), gender, severity (none versus some school attendance at baseline) and comorbid anxiety (> or ≤12 on the HADS anxiety subscale) for the primary outcome, by adding an interaction term to the primary analysis multivariable linear regression model.
Health economic analyses
We conducted a cost-utility analysis of SMC+LP from the health service and public sector perspective. We estimated the incremental net monetary benefit (iNMB) of SMC+LP versus SMC, at a threshold willingness-to-pay of £20,000 (~US$30,000) per QALY 33 . 34 . In the primary analysis, we used the cost of LP charged to the trial (mean £567). In sensitivity analyses we: (1) used the price of LP outside of trial (£620; July 2014 price); (2) estimated cost of providing the LP intervention within the UK health service (Web Table 12 ). SMC outpatient attendances were extracted from hospital records. Other healthcare use was based on parent-report. Resource use was combined with 2013 unit costs (Web Table 12 ) 34-3735-38 . In the absence of a paediatric valuation for the EQ-5D-Y, we used the UK adult tariff 38 . QALYs were estimated using the area under the curve 39 . 39 . QALYs were estimated using the area under the curve 40 . Incremental costs, QALYs and net benefits were adjusted for baseline values, age, gender and for variables where there was baseline imbalance.
Non-parametric bootstrapping methods were used to calculate normally distributed 95% confidence intervals around the iNMB. The probability that SMC+LP is cost-effective at varying willingness-topay thresholds was estimated using a cost-effectiveness acceptability curve. Where one item of the 
RESULTS
Of 657 children assessed in the specialist CFS/ME clinic during the recruitment period, 631 were assessed for study eligibility and 310 were eligible (Figure 1 ). Among those eligible 136 consented to receiving further information and 100 were randomized: 49 to SMC only and 51 to SMC+LP.
Recruitment was stopped after the 100 th participant was randomized. 56 of these participants were included in the report of whether it was feasible to conduct this RCT. 24 Recruitment was stopped after the 100 th participant was randomized. Eligible children and adolescents who found out more about the trial but were not randomized had lower anxiety and depression scores and attended more school (Web Table 23 ). Participants' mean age was 14 years, 76 were female and all described themselves as British. Participants were disabled by their fatigue: only seven were attending full time school and 47 described themselves as attending two days or less school a week.
Participants' characteristics at baseline were balanced between arms except for pain and anxiety (SCAS) scores (Table 1) , which was adjusted for in sensitivity analyses. The imbalance in pain and SCAS scores were in opposite directions suggesting that the two arms were not systematically different. Five participants withdrew from the study: two from the SMC and three from the SMC+LP arm. Outcome data were collected from 92 participants on at least one follow-up occasion. Baseline characteristics were similar between those who did (n=82) and did not (n=18) provide primary outcome data at six months (Web Table 34 ). The mean (SD) time between clinical assessment and primary outcome collection was 6.8 (1.0) and 6.8 (0.7) months in the SMC and SMC + LP arms respectively. Treatment as allocated was received by 46 (94%) and 39 (76%) participants in the SMC and SMC+LP arms respectively. Three participants (3/39, 8%) in the SMC+LP arm received the LP course after completing the 6 month follow-up, these participants were included in the analyses.
Mean SF-36 physical function improved more over time in participants allocated to SMC+LP than in those allocated to SMC (Figure 2 ). Participants allocated to SMC+ LP had better physical function at six months than those allocated to SMC ( Table 2 , adjusted difference in means 12.5 [95% CI 4.5, 20.5], p=0.003). This difference increased to 15.1 (95% CI 5.8, 24.4, p=0.002) at 12 months. These differences were similar when additionally adjusted for baseline anxiety (SCAS) and pain (VAS), when analyses were restricted to participants recruited from February 2011, and with multiple imputation of missing data ( Table 2 ). The average between-arm difference in physical function across both 6 and 12 month follow-up was 14.4 (95% CI 7.3, 21.5),, p<0·001. The ). When compliance was taken into account using CACE analyses, the estimated effect of LP (using CACE analyses) among compliers at 6 and 12 months was increased compared with the ITT estimate ( (Table 3) respectively). However the difference in means in SCAS anxiety was greater at 12 months (-12·1
[95% CI -20·1, -4·1] and there was evidence that there was less depression among participants allocated to SMC+LP than those allocated to SMC at 12 months (adjusted difference in means in HADS depression score -1.7 [95% CI -3·3, -0·2] p=0.03003). Participants allocated to SMC+LP had better school attendance at 12 months than those allocated to SMC (adjusted difference in means 0.9 days of school per week [95% CI 0.2, 1.6] p=0.018). Pain02). Mean pain scores were lower in participants allocated to SMC+LP compared with those allocated to SMC at both six and 12 months, but confidence intervals were wide.
Five adverse events were reported (three in the SMC+LP arm). Four were related to participants and one to a parent. None were attributed to either SMC or LP. Physical function at six months deteriorated in nine participants, of whom eight were in the SMC arm. Five of the nine had deterioration of ≤ 10 on the SF-36 physical function subscale (range 0-100) which is less than the Minimal Clinically Important Difference (MCID).
EQ-5D-Y questionnaires were completed by 65, 82 and 80 participants at three, six and 12 months respectively ( Figure 3) ; 56 completed EQ-5D-Y at all three follow-up time points. EQ-5D-Y scores were generally higher in the SMC+LP group. Differences in quality-adjusted life year (QALYs) were evident at 12 months in the multiple imputation dataset ( Complete healthcare use questionnaires were returned by between 55 (55% at 12 months) and 56 (56%56 participants at 3 and 6 months) participants and 55 at 12 months, but only 30 (30%)participants completed these questionnaires at all three time points (see web table 5 for details).. The initial cost of LP was not fully offset by marginally lower costs of other care over the 12 month period. The incremental cost (Table 4 ) of SMC+LP was higher in both complete case (difference in means £445, [95% CI -57 to 947], p=0.08208) and multiple imputation datasets (difference in means £390, [95% CI 189 to 591], p=<0.000005). Table 4 shows that in the multiple imputation dataset there was good evidence that SMC+LP was more cost-effective than SMC alone (incremental net monetary benefit (iNMB) £1508, [95% CI £148
to £2869], p=0.03403), although the evidence was much weaker in the complete case dataset (Figure 4 , web table 6). Sensitivity analyses varying the unit cost of LP treatment made no difference to this conclusion (Web Table 6 , Web figure 17 ). Sensitivity analyses assuming costs and QALYs are not missing at random 40 did not alterreduced the conclusionstrength of the evidence that SMC+LP was likely to be cost-effective, but reduceddid not alter the strength of the evidenceconclusion.
DISCUSSION
This is the first randomized trial investigating the effectiveness of the Lightning Process for any condition. It is the first trial that has demonstrated the effectiveness of an intervention other than CBT for paediatric CFS/ME. Addition of the Lightning Process to Specialist Medical Care improved physical function at 6 months in adolescents with CFS/ME and this difference increased at 12
months. The addition of LP also improved fatigue and anxiety at six months and fatigue, anxiety and depression at 12 months. Participants in the LP arm were attending one day more of school a week at 12 months on average. The initial cost of LP was not fully offset by lower subsequent costs of health care, but the improvements in health-related quality of life meant that SMC+LP is probably cost-effective using a threshold for a quality-adjusted life years of £20,000 (~US $30,000).
Participants in the SMILE trial did not have any serious adverse events attributable to either treatment arm. The majority of those who experienced a deterioration in physical function had a deterioration of ≤ 10 on the SF-36 physical function subscale. The lack of serious adverse events is consistent with other treatment trials in CFS/ME 4041 .
Strengths of the study include its randomized design and that we followed patientsfollow up for 12 months. Participants received specialist medical care that is currently being delivered in the UK Health Service by a multidisciplinary team, and the Lightning Process as it is currently provided.
More participants were lost to follow-up in the SMC arm, but baseline characteristics were similar in those followed and not followed up. Complete healthcare use questionnaires were returned by only 55 or 56 participants at each time point. We used multiple imputation to correct for potential bias due to missing data and conducted sensitivity analyses restricted to participants recruited after the protocol changed to collect primary outcome data by telephone, which improved follow-up rates suggesting results were robust. We pre-defined the clinically important difference (10 points) on the SF-36-PFS and the difference in means was greater than this at both 6 and 12 months. The study was not blinded, so that patient-reported outcomes may have been affected by participants' knowledge of the group to which they were randomized. Only 36 (70%) of those allocated LP attended the full course prior to the 6 month follow-up but we estimated the effect in all those who completed the full LP course. The study was originally planned as a feasibility study and although randomised, was not registered on a trial registry, since the aim was to investigate feasibility rather than effectiveness of the intervention. After establishing feasibility, we applied to register the full trial in June 2012. At this time, the results of our feasibility work suggested we could use either SF-36-PFS or Chalder Fatigue scale or both which we registered as primary outcomes. We decided to use just the SF-36-PFS and published this in 2013 and in our analyses plan. We did not update the ISTCRN site until 2018, however, we uploaded the relevant publications in 2016 and the study website had the updated analyses plan.
The Lightning Process may not be suitable for all children and adolescents. Fewer than 30% of eligible children were randomized. We do not know why the majority did not want to take part in the trial but it may be because they did not want to take part in groups or travel for three consecutive days. We felt it would be unethical to have a control group without treatment and therefore we only know that LP is effective in addition to specialist medical care and not whether it is effective on its own. We only recruited children aged 12 and over who were not housebound and who spoke English. We do not know whether LP is effective, acceptable or feasible for those who are severely affected, less than 12 years old or do not speak English., or do not speak English. The study was registered after demonstrating feasibility. The analysis includes participants who were recruited prior to registration of the study. This does not comply with ICMJE and BMJ guidance on trial registration. The reasons for this have been explained in the paper.
Participants in both treatment arms improved. Those receiving SMC alone had a mean improvement that was similar to that seen in adults receiving CBT or GET 4041 . The improvement in SF-36-PFS in those receiving SMC+LP is consistent with those receiving treatment in previous paediatric trials investigating both family based and individual CBT 17 20 . We pre-defined the minimally clinically important difference as 10 points on the SF-36-PFS based on consensus statements. Subsequent work by our team has shown that this is a clinically significant change in physical function for children with CFS/ME. 42 Ten points equates to a minimum of two step changes on the SF-36-PFS.
This can be either one step change on two questions, or two step changes on one question. The SF-36 asks: "Does your health limit you in these activities? If so, how much? As an example, one step change could be: "Yes, limited a lot" to "Yes, limited a little" or "Yes, limited a little" to "No, not limited at all" to different questions such as "climbing several flights of stairs" or "walking 100 yards" or "walking half a mile". The participants in our study who received SMC only, did not improve as much as other trials investigating CBT 17 20 which may be because on average they had less than half the number of treatment sessions. As we did not compare LP with either a full course of only CBT or GET we do not know if LP is more of less effective than either of these treatment approaches.
Participants in the SMC+LP arm maintained or increased improvements compared to SMC alone at 12 months and this was true for both the Intention to Treat (ITT) and the Complier Average Causal Effect (CACE) analyses. This is in contrast to previous trials investigating internet based CBT where the treatment effects were sustained but the difference between the two trial arms was reduced at 12 months compared to three months 19 22 and family focused CBT versus psycho-education where treatment differences at three months were not maintained at six or 12 months 20 .
There is only one study 23 investigating LP which used qualitative interviews to explore the views of nine 14-26 year olds about their experiences. The main difference between LP and CBT appears to be the emphasis placed on physiological responses and causal attributions 23 but we do not know whether these explain the greater effectiveness of LP. We do not know which aspects of the LP are the most important or helpful. Some young people who received LP value the theory, others the practical sessions or the homework 23 . Further research is needed to understand why LP improves outcomes at six and 12 months and which aspects of the LP contribute to its effectiveness.
There is only one study 23 investigating LP which used qualitative interviews to explore the views of nine [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] year olds about their experiences. The main difference between LP and CBT appears to be the emphasis placed on physiological responses and causal attributions 23 but we do not know whether these explain the greater effectiveness of LP. We do not know which aspects of the LP are the most important or helpful. Some young people who received LP value the theory, others the practical sessions or the homework 23 . Further research is needed to understand why LP improves outcomes at six and 12 months and which aspects of the LP contribute to its effectiveness.
Conclusions
The addition of the Lightning Process to Specialist Medical Care may be helpful to children with CFS/ME. However, this study needs to be replicated before the Lightning Process should be offered in the NHS.
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What is already known on this topic
Paediatric CFS/ME is relatively common with a negative impact on school, mood and quality of life Even with effective treatment, a significant number of children have not recovered at 6 months The Lightning process is used by children with CFS/ME in the UK but with no evidence of effectivness
What this study adds
At 6 months, children who received LP in addition to SMC had better physical function, fatigue and less anxiety At 12 months, children who received LP in addition to SMC had better fatigue, anxiety, depression and school attendance.
Adding LP is probably cost effective but not all children wish to take part.
